A Granito

A Grothey

D Bettinger

D Tougeron

E Van Cutsem

F Pani

F Petrelli

G Hirano

GG Di Costanzo

J Feliu

J Li

J Sastre

J Tabernero

JY Cho

M Reig

M Scartozzi

M Suenaga

ME Lacouture

OP Hamnvik

R Giampieri

S Krishnamoorthy

S Stintzing

SM Wilhelm

SP Gampenrieder

Scientific Reports

AbstractRegorafenib is an orally administered multikinase inhibitor indicated for the treatment of heavily pretreated metastatic colorectal cancer patients with good performance status, albeit less than 50% treated patients achieve disease stabilisation or better at the first radiological evaluation. In addition to that a particularly broad spectrum of toxicities (experienced as G3 or more NCI CTCAE graded by 50% of patients treated) have led to reconsider its widespread use in the majority of patients. We retrospectively collected data about the magnitude of off-target effects experienced during the first 8-weeks of regorafenib monotherapy and analysed their correlation with overall survival, progression free survival and disease control rate. Our findings suggest that skin rash (Exp (B): 0.52, p = 0.0133) or hypothyroidism (Exp (B): 0.11, p = 0.0349) were significantly correlated with improved overall survival at multivariate regression analysis. It was also demonstrated a statistically significant role of diarrhea as predictor of improved survival but its independent prognostic role was lost at multivariate analysis (Exp (B): 0.63, p = 0.162). This is the first analysis showing a potential correlation between the onset of these forms of side effects and regorafenib efficacy, however sample size limitations and the retrospective nature of our analysis prevent us from drawing definitive conclusions.</jats:p

Riccardo Giampieri

Michela del Prete

Tiziana Prochilo

Marco Puzzoni

Valeria Pusceddu

Fabiana Pani

Elena Maccaroni

Roberta Mascia

Maria Giuditta Baleani

Tania Meletani

Rossana Berardi

Anna Maria Lanzillo

Stefano Mariotti

Alberto Zaniboni

Stefano Cascinu

Mario Scartozzi

Crossref

Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis

Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis

Abstract

Similar works

Full text

Available Versions

Crossref